Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by stock analysts at Needham & Company LLC to $95.00 in a note issued to investors on Tuesday. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target would suggest a potential upside of 25.20% from the stock’s current price.
A number of other equities analysts also recently issued reports on NBIX. Robert W. Baird reaffirmed an “outperform” rating and set a $66.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, September 21st. Jefferies Group reaffirmed a “buy” rating and set a $69.00 price target (up from $66.00) on shares of Neurocrine Biosciences in a research report on Tuesday, October 3rd. BMO Capital Markets reaffirmed an “outperform” rating and set a $84.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, October 5th. Leerink Swann reaffirmed an “outperform” rating and set a $72.00 price target (up from $67.00) on shares of Neurocrine Biosciences in a research report on Tuesday, October 10th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $76.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday, October 25th. One research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $82.31.
Shares of Neurocrine Biosciences (NBIX) traded down $0.21 during trading hours on Tuesday, reaching $75.88. 1,135,600 shares of the company were exchanged, compared to its average volume of 1,125,073. The company has a market capitalization of $6,930.00, a P/E ratio of -34.18 and a beta of 0.35. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences has a 52 week low of $38.43 and a 52 week high of $83.84.
In other news, insider Dimitri E. Grigoriadis sold 30,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the sale, the insider now directly owns 77,691 shares of the company’s stock, valued at $5,794,194.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Darin Lippoldt sold 1,979 shares of the business’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $79.36, for a total transaction of $157,053.44. The disclosure for this sale can be found here. Insiders have sold 116,405 shares of company stock worth $8,588,519 over the last three months. Corporate insiders own 4.80% of the company’s stock.
Large investors have recently bought and sold shares of the business. Crow Point Partners LLC purchased a new stake in Neurocrine Biosciences in the fourth quarter valued at $145,000. The Manufacturers Life Insurance Company boosted its holdings in Neurocrine Biosciences by 7.8% in the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after purchasing an additional 193 shares during the last quarter. Comerica Bank purchased a new stake in Neurocrine Biosciences in the third quarter valued at $210,000. Trexquant Investment LP purchased a new stake in Neurocrine Biosciences in the third quarter valued at $246,000. Finally, World Asset Management Inc purchased a new stake in Neurocrine Biosciences in the third quarter valued at $246,000.
COPYRIGHT VIOLATION WARNING: “Needham & Company LLC Increases Neurocrine Biosciences (NBIX) Price Target to $95.00” was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://weekherald.com/2018/01/18/needham-company-llc-increases-neurocrine-biosciences-nbix-price-target-to-95-00.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.